Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;6(5):669-679.
doi: 10.1007/s41669-022-00359-x. Epub 2022 Aug 23.

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment

Affiliations

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment

Alireza Darrudi et al. Pharmacoecon Open. 2022 Sep.

Abstract

Background and objective: The coronavirus disease 2019 (COVID-19) pandemic is a major international threat and vaccination is the most robust strategy to terminate this crisis. It is helpful for policymakers to be aware of community preferences about vaccines. The present study aims to investigate the public's preferences and willingness to pay for the COVID-19 vaccine in Iran.

Methods: This research is a cross-sectional study performed using a discrete choice experiment for a sample of the public population of several provinces of Iran in 2021. The samples were divided into two groups: one group expressed their preferences regarding the vaccine's attributes, and another group expressed their preferences regarding prioritizing individuals to get the vaccine. The discrete choice experiment design included five attributes including effectiveness, risk of severe complications, price, location of vaccine production, and duration of protection related to preferences for vaccine selection and six attributes including age, underlying diseases, employment in the healthcare sector, the rate of virus spread, the necessary job, and cost to the community related to preferences for prioritizing individuals to get the vaccine. A total of 715 individuals completed the questionnaire. The conditional logit regression model was used to analyze the discrete choice experiment data. Willingness to pay for each attribute was also calculated.

Results: The willingness to pay for the COVID-19 vaccine with 90% (70%) efficacy, the risk of severe complications for 1 (5) person per one million people, imported (domestic) vaccine, and 24-month (12-month) duration of protection attributes was about US$71 (US$37). The preference for vaccination for respondents was enhanced by increasing the efficacy and the duration of vaccine protection and decreasing complications and costs. The likelihood of prioritizing individuals to get a vaccination was increased for a person with an underlying disease, employment in the healthcare sector, the necessary job for the community, the high potential for virus spread in the community, and the high cost of death to the community. The age variable was not statistically significant for prioritizing individuals to get the vaccine.

Conclusions: In the setting of the COVID-19 vaccination program, the public's preferences identified in this study should be considered. The obtained results provide useful information for policymakers to identify individual and social values for an appropriate vaccination strategy.

PubMed Disclaimer

Conflict of interest statement

Alireza Darrudi, Rajabali Daroudi, Masud Yunesian, and Ali Akbari Sari have conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Example of a discrete choice experiment choice set for vaccine selection
Fig. 2
Fig. 2
Example of a discrete choice experiment choice set for prioritizing people. COVID-19 coronavirus disease 2019
Fig. 3
Fig. 3
Willingness to pay of individuals for different levels of attributes of the coronavirus 2019 vaccine based on the conditional logit model

References

    1. Lim WS, Liang CK, Assantachai P, Auyeung TW, Kang L, Lee WJ, et al. COVID-19 and older people in Asia: Asian Working Group for Sarcopenia calls to action. Geriatr Gerontol Int. 2020;20(6):547–558. doi: 10.1111/ggi.13939. - DOI - PMC - PubMed
    1. Worldometer. COVID-19 data. 2021. https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1. Accessed 20 Nov 2021.
    1. Worldometer. COVID-19 data. 2021. Available from: https://www.worldometers.info/coronavirus/country/iran/https://www.world.... Accessed 20 Nov 2021.
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
    1. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed

LinkOut - more resources